Celltrion: Positive top-line results in Phase III trial of regdanvimab anti-COVID-19 monoclonal antibody

 

• Regdanvimab (CT-P59) (40mg/kg) achieved statistically significant and clinically meaningful results in four main endpoints including primary and three key secondary endpoints; the company anticipates full Phase III data to be released in the coming months
• Regdanvimab (CT-P59) significantly reduced the risk of COVID-19 related hospitalisation or death by 72% for patients at high- risk of progressing to severe COVID-19 and 70% for all patients
• Patients who were treated with regdanvimab (CT-P59) reported a significantly shortened time to clinical recovery by at least 4.7 days quicker for patients at high- risk of progressing to severe COVID-19 and by 4.9 days quicker compared to placebo for all patients
• According to the recently published article from Biochemical and Biophysical Research Communications, sufficient antiviral effect in B.1.351 variant (now classified by the WHO as Beta)-infected animals was confirmed with a clinical dosage of regdanvimab (CT-P59)¹

https://www.biospace.com/article/releases/celltrion-announces-positive-top-line-results-from-global-phase-iii-trial-of-regdanvimab-ct-p59-an-anti-covid-19-monoclonal-antibody-treatment-/